Immutep Limited

NASDAQ:IMMP

Biotechnology

Healthcare
$0.37 +0.64%

+$0.00 today

Market cap
$55.01M
Beta
2.24
P/E (TTM)
-0.9
EPS (TTM)
-$0.06
52W Low $0.29High $3.53

Volume 3.10M

Average 13.46M

IMMP EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Immutep LimitedNASDAQ: IMMP

EBITDA · Q2 FY2026 · quarter ended Dec 2025

EBITDA remains negative

Q2 FY2026 EBITDA was -A$44.9M, compared with -A$26.39M a year earlier.

Context

  • EBITDA amounted to 1246.6% of revenue in FY2025, up 87.2 pp from a year earlier.
  • EBITDA grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 3 analysts of -A$33.36M (+46.9%) for the fiscal year ending Jun 2026, a step up from the -41.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-A$44.9M— QoQ
Last fiscal yearJun 2025
-A$62.88M-41.2% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-70.1%——
1 year-41.2%+46.9%+88.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

AUD · from the income statement

Latest · FY2025
(62.88M) AUD
Year-over-year change
-41.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How IMMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -41.2% is the 7th highest of 11, against a peer median of -25.6%.
  • EBITDA amounts to 1246.6% of revenue for IMMP, versus a peer median of 319.0%.
IMMP Competitors
EBITDA for IMMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$893.33M USD+1767.7%——
MREOMereo BioPharma Group plcLTM Mar 2026-$39.29M USD+13.4%—7858.4%
PRQRProQR Therapeutics N.V.LTM Mar 2026-€42.88M EUR-67.7%—319.0%
CADLCandel Therapeutics, Inc.LTM Mar 2026-$50.3M USD-36.5%——
ACHVAchieve Life Sciences, Inc.LTM Mar 2026-$50.86M USD-14.6%——
IMMPImmutep LimitedFY2025-A$62.88M AUD-41.2%—1246.6%
EDITEditas Medicine, Inc.LTM Mar 2026-$100.08M USD+56.8%—258.7%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026-$136.24M USD-213.5%—62.6%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$160.41M USD+32.7%——
TRDAEntrada Therapeutics, Inc.LTM Mar 2026-$164.87M USD-697.5%—2873.3%
CABACabaletta Bio, Inc.LTM Mar 2026-$171.58M USD-48.1%——
Peer median (excluding IMMP) —-25.6%—319.0%

Competitors are the stored peer set for IMMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

AUD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue3.86M170.37K3.51M3.84M5.04M
Cost of Revenue17.24M2.06M2.06M41.55M61.41M
Gross Profit(13.37M)(1.89M)1.44M(37.7M)(56.37M)
Gross Margin-346.2%-1111.2%41.2%-981.4%-1117.6%
Research & Development17.24M31.34M28.79M41.55M61.41M
Selling, General & Admin6.28M7.21M14.08M8.85M8.64M
Operating Expenses18.3M32.55M44.94M50.4M70.06M
Depreciation & Amortization1.89M1.84M1.86M2.01M2.13M
EBITDA(17.77M)(31.87M)(39.57M)(44.54M)(62.88M)
EBITDA Margin-460.0%-18708.9%-1128.8%-1159.4%-1246.6%
Operating Income(31.68M)(33.94M)(77.69M)(88.1M)(126.42M)
Operating Margin-820.0%-19920.0%-2216.0%-2293.3%-2506.5%
Interest Income105.33K224.52K939K3.88M5.25M
Interest Expense9.83K92.43K20.4K30.59K24.01K
Other Income / Expenses1.77M1.63M37.79M45.39M64.99M
Income Before Tax(29.9M)(32.21M)(39.9M)(42.72M)(61.43M)
Pre-Tax Margin-774.1%-18906.5%-1138.0%-1111.9%-1218.0%
Income Tax Expense3334000
Net Income(29.9M)(32.21M)(39.9M)(42.72M)(61.43M)
Net Margin-774.1%-18906.5%-1138.0%-1111.9%-1218.0%
EPS (Basic)(0.49)(0.37)(0.44)(0.36)(0.42)
EPS (Diluted)(0.49)(0.37)(0.44)(0.36)(0.42)
Weighted Avg Shares60.43M86.23M90.06M119.99M145.58M
Weighted Avg Shares (Diluted)60.43M86.23M90.06M120.11M145.58M

Immutep Limited

NASDAQ:IMMP

Intrinsic Alpha fair value

Locked

Current Price

$0.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.